Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study
Hepatic venous pressure gradient (HVPG) of 10 mmHg or greater is the gold standard for the assessment of clinically significant portal hypertension, which is a crucial stage in cirrhosis. However, the measurement of HVPG is invasive and not feasible to all patients with cirrhosis. We aimed to invest...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2019-10, Vol.394, p.S75-S75 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S75 |
|---|---|
| container_issue | |
| container_start_page | S75 |
| container_title | The Lancet (British edition) |
| container_volume | 394 |
| creator | Liu, Yanna Tang, Tianyu Huang, Yifei Ji, Jiansong Yu, Qian Meng, Xiangpan Liu, Jinqiang Liu, Dengxiang Liu, Changchun Liu, Chuan Shao, Ruoyang Zhang, Chunqing Wang, Wenhui Wang, Zhiwei Wang, Weidong Yuan, Min Li, Lei Zuo, Changzeng Wang, Jitao Zhao, Zhongwei Wang, Guangchuan Li, Mingxing Liu, Qingbo Lei, Junqiang An, Weimin Ju, Shenghong Qi, Xiaolong |
| description | Hepatic venous pressure gradient (HVPG) of 10 mmHg or greater is the gold standard for the assessment of clinically significant portal hypertension, which is a crucial stage in cirrhosis. However, the measurement of HVPG is invasive and not feasible to all patients with cirrhosis. We aimed to investigate whether the non-invasive score on the basis of non-contrast-enhanced MRI (CHESS-CSPHMRI score) can predict the presence of clinically significant portal hypertension in patients with cirrhosis.
In this prospective, multicentre, diagnostic study, patients with cirrhosis who were scheduled to undergo HVPG measurements and non-contrast-enhanced MRI were recruited from eight university hospitals in China between Dec 4, 2019, and April 30, 2019. Participants receiving non-contrast-enhanced MRI and without history of chronic liver diseases were recruited as healthy controls. The calculation of CHESS-CSPHMRI score included: (1) region of interest segmentation of the left frontal lobe of the liver on T1-weighted MRI maps; (2) liver tissues identification by histogram analysis; (3) detection of the liver edge; (4) liver surface matching using a least squares method; (5) calculation of the norm of residuals between the edge pixels and the matched surface; and (6) CHESS-CSPHMRI score was calculated on the basis of the norm of residuals and the number of the pixels detected on the edge of the liver. The diagnostic performance of CHESS-CSPHMRI score was assessed using area under the receiver operating characteristic (ROC) curve. This study was approved by all the local institutional review boards with written informed consent obtained from the participants. This study is registered with ClinicalTrials.gov, 03766880.
We enrolled 260 participants with cirrhosis, including 110 healthy controls. The calculation of CHESS-CSPHMRI score in participants with or without clinically significant portal hypertension could be done within a few seconds. In the prediction of clinically significant portal hypertension, the area under the ROC curve was 0·81 (95% CI 0·75–0·86), sensitivity was 0·82 (95% CI 0·75–0·88), and specificity of CHESS-CSPHMRI score was 0·70 (95% CI 0·61–0·77). Additionally, we found a positive correlation between CHESS-CSPHMRI score and HVPG (r=0·385, p |
| doi_str_mv | 10.1016/S0140-6736(19)32411-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2306781630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673619324110</els_id><sourcerecordid>2306781630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2290-741c1f1953ff7cf9673dcdc2737119334dd61271995ed398044498b4a37c50063</originalsourceid><addsrcrecordid>eNqFUctqHDEQFCaBbJx8QkCQiw0ZRz3SjFa5hLD4BU4C3gRyE7IetsxYGkuahf0c_6k1uyZXn5qmq6uruhD6BOQECPRf1wQYaXpO-yMQx7RlAA05QAtgnDUd4__eoMV_yDv0Pud7QgjrSbdAT79iaHzYqOw3Fmcdk8VT9uEWhzrQMZSkcmlsuFNBW4N_Xl9iFxP2xobindeq-BhwdFgPPtR2GLY4-9uwm4WCx5iKGvDddrSp2JBn9NHq4nS9hiVpj79hhccU82h1qQq-4IdpKF5X8iokl8lsP6C3Tg3Zfnyph-jv2emf1UVz9fv8cvXjqtFtK0jDGWhwIDrqHNdOVK9GG91yygEEpcyYHloOQnTWULEkjDGxvGGKct0R0tND9HnPW-U8TjYXeR-nFOpJ2VLS8yX0lFRUt0fpKjon6-SY_INKWwlEzmnIXRpyfrUEIXdpyHnv-37PVgsbb5PM2tv5pT5V69JE_wrDM9hfkoY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2306781630</pqid></control><display><type>article</type><title>Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study</title><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Liu, Yanna ; Tang, Tianyu ; Huang, Yifei ; Ji, Jiansong ; Yu, Qian ; Meng, Xiangpan ; Liu, Jinqiang ; Liu, Dengxiang ; Liu, Changchun ; Liu, Chuan ; Shao, Ruoyang ; Zhang, Chunqing ; Wang, Wenhui ; Wang, Zhiwei ; Wang, Weidong ; Yuan, Min ; Li, Lei ; Zuo, Changzeng ; Wang, Jitao ; Zhao, Zhongwei ; Wang, Guangchuan ; Li, Mingxing ; Liu, Qingbo ; Lei, Junqiang ; An, Weimin ; Ju, Shenghong ; Qi, Xiaolong</creator><creatorcontrib>Liu, Yanna ; Tang, Tianyu ; Huang, Yifei ; Ji, Jiansong ; Yu, Qian ; Meng, Xiangpan ; Liu, Jinqiang ; Liu, Dengxiang ; Liu, Changchun ; Liu, Chuan ; Shao, Ruoyang ; Zhang, Chunqing ; Wang, Wenhui ; Wang, Zhiwei ; Wang, Weidong ; Yuan, Min ; Li, Lei ; Zuo, Changzeng ; Wang, Jitao ; Zhao, Zhongwei ; Wang, Guangchuan ; Li, Mingxing ; Liu, Qingbo ; Lei, Junqiang ; An, Weimin ; Ju, Shenghong ; Qi, Xiaolong</creatorcontrib><description>Hepatic venous pressure gradient (HVPG) of 10 mmHg or greater is the gold standard for the assessment of clinically significant portal hypertension, which is a crucial stage in cirrhosis. However, the measurement of HVPG is invasive and not feasible to all patients with cirrhosis. We aimed to investigate whether the non-invasive score on the basis of non-contrast-enhanced MRI (CHESS-CSPHMRI score) can predict the presence of clinically significant portal hypertension in patients with cirrhosis.
In this prospective, multicentre, diagnostic study, patients with cirrhosis who were scheduled to undergo HVPG measurements and non-contrast-enhanced MRI were recruited from eight university hospitals in China between Dec 4, 2019, and April 30, 2019. Participants receiving non-contrast-enhanced MRI and without history of chronic liver diseases were recruited as healthy controls. The calculation of CHESS-CSPHMRI score included: (1) region of interest segmentation of the left frontal lobe of the liver on T1-weighted MRI maps; (2) liver tissues identification by histogram analysis; (3) detection of the liver edge; (4) liver surface matching using a least squares method; (5) calculation of the norm of residuals between the edge pixels and the matched surface; and (6) CHESS-CSPHMRI score was calculated on the basis of the norm of residuals and the number of the pixels detected on the edge of the liver. The diagnostic performance of CHESS-CSPHMRI score was assessed using area under the receiver operating characteristic (ROC) curve. This study was approved by all the local institutional review boards with written informed consent obtained from the participants. This study is registered with ClinicalTrials.gov, 03766880.
We enrolled 260 participants with cirrhosis, including 110 healthy controls. The calculation of CHESS-CSPHMRI score in participants with or without clinically significant portal hypertension could be done within a few seconds. In the prediction of clinically significant portal hypertension, the area under the ROC curve was 0·81 (95% CI 0·75–0·86), sensitivity was 0·82 (95% CI 0·75–0·88), and specificity of CHESS-CSPHMRI score was 0·70 (95% CI 0·61–0·77). Additionally, we found a positive correlation between CHESS-CSPHMRI score and HVPG (r=0·385, p<0·0001).
The CHESS-CSPHMRI score could be used to rapidly and accurately detect clinically significant portal hypertension in patients with cirrhosis using non-contrast-enhanced MRI.
National Natural Science Foundation for Distinguished Young Scholars of China, National Natural Science Foundation of China, Guangdong Science Fund for Distinguished Young Scholars, Guangzhou Industry-Academia-Research Collaborative Innovation Major Project.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(19)32411-0</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Cirrhosis ; Clinical significance ; Correlation analysis ; Diagnostic systems ; Frontal lobe ; Histograms ; Hypertension ; Image processing ; Informed consent ; Least squares method ; Liver ; Liver cirrhosis ; Liver diseases ; Magnetic resonance imaging ; Mathematical analysis ; Pixels ; Review boards ; Segmentation ; Surface matching</subject><ispartof>The Lancet (British edition), 2019-10, Vol.394, p.S75-S75</ispartof><rights>2019 Elsevier Ltd</rights><rights>2019. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2290-741c1f1953ff7cf9673dcdc2737119334dd61271995ed398044498b4a37c50063</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2306781630?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64368,72218</link.rule.ids></links><search><creatorcontrib>Liu, Yanna</creatorcontrib><creatorcontrib>Tang, Tianyu</creatorcontrib><creatorcontrib>Huang, Yifei</creatorcontrib><creatorcontrib>Ji, Jiansong</creatorcontrib><creatorcontrib>Yu, Qian</creatorcontrib><creatorcontrib>Meng, Xiangpan</creatorcontrib><creatorcontrib>Liu, Jinqiang</creatorcontrib><creatorcontrib>Liu, Dengxiang</creatorcontrib><creatorcontrib>Liu, Changchun</creatorcontrib><creatorcontrib>Liu, Chuan</creatorcontrib><creatorcontrib>Shao, Ruoyang</creatorcontrib><creatorcontrib>Zhang, Chunqing</creatorcontrib><creatorcontrib>Wang, Wenhui</creatorcontrib><creatorcontrib>Wang, Zhiwei</creatorcontrib><creatorcontrib>Wang, Weidong</creatorcontrib><creatorcontrib>Yuan, Min</creatorcontrib><creatorcontrib>Li, Lei</creatorcontrib><creatorcontrib>Zuo, Changzeng</creatorcontrib><creatorcontrib>Wang, Jitao</creatorcontrib><creatorcontrib>Zhao, Zhongwei</creatorcontrib><creatorcontrib>Wang, Guangchuan</creatorcontrib><creatorcontrib>Li, Mingxing</creatorcontrib><creatorcontrib>Liu, Qingbo</creatorcontrib><creatorcontrib>Lei, Junqiang</creatorcontrib><creatorcontrib>An, Weimin</creatorcontrib><creatorcontrib>Ju, Shenghong</creatorcontrib><creatorcontrib>Qi, Xiaolong</creatorcontrib><title>Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study</title><title>The Lancet (British edition)</title><description>Hepatic venous pressure gradient (HVPG) of 10 mmHg or greater is the gold standard for the assessment of clinically significant portal hypertension, which is a crucial stage in cirrhosis. However, the measurement of HVPG is invasive and not feasible to all patients with cirrhosis. We aimed to investigate whether the non-invasive score on the basis of non-contrast-enhanced MRI (CHESS-CSPHMRI score) can predict the presence of clinically significant portal hypertension in patients with cirrhosis.
In this prospective, multicentre, diagnostic study, patients with cirrhosis who were scheduled to undergo HVPG measurements and non-contrast-enhanced MRI were recruited from eight university hospitals in China between Dec 4, 2019, and April 30, 2019. Participants receiving non-contrast-enhanced MRI and without history of chronic liver diseases were recruited as healthy controls. The calculation of CHESS-CSPHMRI score included: (1) region of interest segmentation of the left frontal lobe of the liver on T1-weighted MRI maps; (2) liver tissues identification by histogram analysis; (3) detection of the liver edge; (4) liver surface matching using a least squares method; (5) calculation of the norm of residuals between the edge pixels and the matched surface; and (6) CHESS-CSPHMRI score was calculated on the basis of the norm of residuals and the number of the pixels detected on the edge of the liver. The diagnostic performance of CHESS-CSPHMRI score was assessed using area under the receiver operating characteristic (ROC) curve. This study was approved by all the local institutional review boards with written informed consent obtained from the participants. This study is registered with ClinicalTrials.gov, 03766880.
We enrolled 260 participants with cirrhosis, including 110 healthy controls. The calculation of CHESS-CSPHMRI score in participants with or without clinically significant portal hypertension could be done within a few seconds. In the prediction of clinically significant portal hypertension, the area under the ROC curve was 0·81 (95% CI 0·75–0·86), sensitivity was 0·82 (95% CI 0·75–0·88), and specificity of CHESS-CSPHMRI score was 0·70 (95% CI 0·61–0·77). Additionally, we found a positive correlation between CHESS-CSPHMRI score and HVPG (r=0·385, p<0·0001).
The CHESS-CSPHMRI score could be used to rapidly and accurately detect clinically significant portal hypertension in patients with cirrhosis using non-contrast-enhanced MRI.
National Natural Science Foundation for Distinguished Young Scholars of China, National Natural Science Foundation of China, Guangdong Science Fund for Distinguished Young Scholars, Guangzhou Industry-Academia-Research Collaborative Innovation Major Project.</description><subject>Cirrhosis</subject><subject>Clinical significance</subject><subject>Correlation analysis</subject><subject>Diagnostic systems</subject><subject>Frontal lobe</subject><subject>Histograms</subject><subject>Hypertension</subject><subject>Image processing</subject><subject>Informed consent</subject><subject>Least squares method</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Magnetic resonance imaging</subject><subject>Mathematical analysis</subject><subject>Pixels</subject><subject>Review boards</subject><subject>Segmentation</subject><subject>Surface matching</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUctqHDEQFCaBbJx8QkCQiw0ZRz3SjFa5hLD4BU4C3gRyE7IetsxYGkuahf0c_6k1uyZXn5qmq6uruhD6BOQECPRf1wQYaXpO-yMQx7RlAA05QAtgnDUd4__eoMV_yDv0Pud7QgjrSbdAT79iaHzYqOw3Fmcdk8VT9uEWhzrQMZSkcmlsuFNBW4N_Xl9iFxP2xobindeq-BhwdFgPPtR2GLY4-9uwm4WCx5iKGvDddrSp2JBn9NHq4nS9hiVpj79hhccU82h1qQq-4IdpKF5X8iokl8lsP6C3Tg3Zfnyph-jv2emf1UVz9fv8cvXjqtFtK0jDGWhwIDrqHNdOVK9GG91yygEEpcyYHloOQnTWULEkjDGxvGGKct0R0tND9HnPW-U8TjYXeR-nFOpJ2VLS8yX0lFRUt0fpKjon6-SY_INKWwlEzmnIXRpyfrUEIXdpyHnv-37PVgsbb5PM2tv5pT5V69JE_wrDM9hfkoY</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Liu, Yanna</creator><creator>Tang, Tianyu</creator><creator>Huang, Yifei</creator><creator>Ji, Jiansong</creator><creator>Yu, Qian</creator><creator>Meng, Xiangpan</creator><creator>Liu, Jinqiang</creator><creator>Liu, Dengxiang</creator><creator>Liu, Changchun</creator><creator>Liu, Chuan</creator><creator>Shao, Ruoyang</creator><creator>Zhang, Chunqing</creator><creator>Wang, Wenhui</creator><creator>Wang, Zhiwei</creator><creator>Wang, Weidong</creator><creator>Yuan, Min</creator><creator>Li, Lei</creator><creator>Zuo, Changzeng</creator><creator>Wang, Jitao</creator><creator>Zhao, Zhongwei</creator><creator>Wang, Guangchuan</creator><creator>Li, Mingxing</creator><creator>Liu, Qingbo</creator><creator>Lei, Junqiang</creator><creator>An, Weimin</creator><creator>Ju, Shenghong</creator><creator>Qi, Xiaolong</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>201910</creationdate><title>Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study</title><author>Liu, Yanna ; Tang, Tianyu ; Huang, Yifei ; Ji, Jiansong ; Yu, Qian ; Meng, Xiangpan ; Liu, Jinqiang ; Liu, Dengxiang ; Liu, Changchun ; Liu, Chuan ; Shao, Ruoyang ; Zhang, Chunqing ; Wang, Wenhui ; Wang, Zhiwei ; Wang, Weidong ; Yuan, Min ; Li, Lei ; Zuo, Changzeng ; Wang, Jitao ; Zhao, Zhongwei ; Wang, Guangchuan ; Li, Mingxing ; Liu, Qingbo ; Lei, Junqiang ; An, Weimin ; Ju, Shenghong ; Qi, Xiaolong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2290-741c1f1953ff7cf9673dcdc2737119334dd61271995ed398044498b4a37c50063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cirrhosis</topic><topic>Clinical significance</topic><topic>Correlation analysis</topic><topic>Diagnostic systems</topic><topic>Frontal lobe</topic><topic>Histograms</topic><topic>Hypertension</topic><topic>Image processing</topic><topic>Informed consent</topic><topic>Least squares method</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Magnetic resonance imaging</topic><topic>Mathematical analysis</topic><topic>Pixels</topic><topic>Review boards</topic><topic>Segmentation</topic><topic>Surface matching</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Yanna</creatorcontrib><creatorcontrib>Tang, Tianyu</creatorcontrib><creatorcontrib>Huang, Yifei</creatorcontrib><creatorcontrib>Ji, Jiansong</creatorcontrib><creatorcontrib>Yu, Qian</creatorcontrib><creatorcontrib>Meng, Xiangpan</creatorcontrib><creatorcontrib>Liu, Jinqiang</creatorcontrib><creatorcontrib>Liu, Dengxiang</creatorcontrib><creatorcontrib>Liu, Changchun</creatorcontrib><creatorcontrib>Liu, Chuan</creatorcontrib><creatorcontrib>Shao, Ruoyang</creatorcontrib><creatorcontrib>Zhang, Chunqing</creatorcontrib><creatorcontrib>Wang, Wenhui</creatorcontrib><creatorcontrib>Wang, Zhiwei</creatorcontrib><creatorcontrib>Wang, Weidong</creatorcontrib><creatorcontrib>Yuan, Min</creatorcontrib><creatorcontrib>Li, Lei</creatorcontrib><creatorcontrib>Zuo, Changzeng</creatorcontrib><creatorcontrib>Wang, Jitao</creatorcontrib><creatorcontrib>Zhao, Zhongwei</creatorcontrib><creatorcontrib>Wang, Guangchuan</creatorcontrib><creatorcontrib>Li, Mingxing</creatorcontrib><creatorcontrib>Liu, Qingbo</creatorcontrib><creatorcontrib>Lei, Junqiang</creatorcontrib><creatorcontrib>An, Weimin</creatorcontrib><creatorcontrib>Ju, Shenghong</creatorcontrib><creatorcontrib>Qi, Xiaolong</creatorcontrib><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Yanna</au><au>Tang, Tianyu</au><au>Huang, Yifei</au><au>Ji, Jiansong</au><au>Yu, Qian</au><au>Meng, Xiangpan</au><au>Liu, Jinqiang</au><au>Liu, Dengxiang</au><au>Liu, Changchun</au><au>Liu, Chuan</au><au>Shao, Ruoyang</au><au>Zhang, Chunqing</au><au>Wang, Wenhui</au><au>Wang, Zhiwei</au><au>Wang, Weidong</au><au>Yuan, Min</au><au>Li, Lei</au><au>Zuo, Changzeng</au><au>Wang, Jitao</au><au>Zhao, Zhongwei</au><au>Wang, Guangchuan</au><au>Li, Mingxing</au><au>Liu, Qingbo</au><au>Lei, Junqiang</au><au>An, Weimin</au><au>Ju, Shenghong</au><au>Qi, Xiaolong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study</atitle><jtitle>The Lancet (British edition)</jtitle><date>2019-10</date><risdate>2019</risdate><volume>394</volume><spage>S75</spage><epage>S75</epage><pages>S75-S75</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>Hepatic venous pressure gradient (HVPG) of 10 mmHg or greater is the gold standard for the assessment of clinically significant portal hypertension, which is a crucial stage in cirrhosis. However, the measurement of HVPG is invasive and not feasible to all patients with cirrhosis. We aimed to investigate whether the non-invasive score on the basis of non-contrast-enhanced MRI (CHESS-CSPHMRI score) can predict the presence of clinically significant portal hypertension in patients with cirrhosis.
In this prospective, multicentre, diagnostic study, patients with cirrhosis who were scheduled to undergo HVPG measurements and non-contrast-enhanced MRI were recruited from eight university hospitals in China between Dec 4, 2019, and April 30, 2019. Participants receiving non-contrast-enhanced MRI and without history of chronic liver diseases were recruited as healthy controls. The calculation of CHESS-CSPHMRI score included: (1) region of interest segmentation of the left frontal lobe of the liver on T1-weighted MRI maps; (2) liver tissues identification by histogram analysis; (3) detection of the liver edge; (4) liver surface matching using a least squares method; (5) calculation of the norm of residuals between the edge pixels and the matched surface; and (6) CHESS-CSPHMRI score was calculated on the basis of the norm of residuals and the number of the pixels detected on the edge of the liver. The diagnostic performance of CHESS-CSPHMRI score was assessed using area under the receiver operating characteristic (ROC) curve. This study was approved by all the local institutional review boards with written informed consent obtained from the participants. This study is registered with ClinicalTrials.gov, 03766880.
We enrolled 260 participants with cirrhosis, including 110 healthy controls. The calculation of CHESS-CSPHMRI score in participants with or without clinically significant portal hypertension could be done within a few seconds. In the prediction of clinically significant portal hypertension, the area under the ROC curve was 0·81 (95% CI 0·75–0·86), sensitivity was 0·82 (95% CI 0·75–0·88), and specificity of CHESS-CSPHMRI score was 0·70 (95% CI 0·61–0·77). Additionally, we found a positive correlation between CHESS-CSPHMRI score and HVPG (r=0·385, p<0·0001).
The CHESS-CSPHMRI score could be used to rapidly and accurately detect clinically significant portal hypertension in patients with cirrhosis using non-contrast-enhanced MRI.
National Natural Science Foundation for Distinguished Young Scholars of China, National Natural Science Foundation of China, Guangdong Science Fund for Distinguished Young Scholars, Guangzhou Industry-Academia-Research Collaborative Innovation Major Project.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S0140-6736(19)32411-0</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2019-10, Vol.394, p.S75-S75 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_2306781630 |
| source | Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Cirrhosis Clinical significance Correlation analysis Diagnostic systems Frontal lobe Histograms Hypertension Image processing Informed consent Least squares method Liver Liver cirrhosis Liver diseases Magnetic resonance imaging Mathematical analysis Pixels Review boards Segmentation Surface matching |
| title | Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T00%3A49%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-invasive%20score%20using%20non-contrast-enhanced%20MRI%20for%20identification%20of%20clinically%20significant%20portal%20hypertension%20(CHESS1802):%20a%20prospective,%20multicentre%20study&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Liu,%20Yanna&rft.date=2019-10&rft.volume=394&rft.spage=S75&rft.epage=S75&rft.pages=S75-S75&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(19)32411-0&rft_dat=%3Cproquest_cross%3E2306781630%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2306781630&rft_id=info:pmid/&rft_els_id=S0140673619324110&rfr_iscdi=true |